HXE
Viewing r1 — May 7, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
HXE (hydroxetamine) is an emerging synthetic dissociative of the arylcyclohexylamine class. It is the primary metabolite of methoxetamine, roughly twice as potent at the NMDA.[1] HXE is an NMDA receptor antagonist, producing its effects by blocking glutamate signaling in the brain's thalamocortical relay system.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
ketamine, methoxetamine, PCP +2 moreketamine, methoxetamine, PCP, dextromethorphan, deschloroketamine show less
HXE was first identified in 2013 as the primary urinary metabolite of methoxetamine, not as a drug in its own right.[2][3] Following progressive international scheduling of MXE, HXE appeared on designer drug markets as a standalone substance in late 2019. It circulates among research chemical users and has been linked to adverse events including deaths since 2021.[4]
Subjective effects include dissociation, cognitive disconnection, derealization, analgesia, and perceptual distortion. The experience is characterized by a warm, sedating quality with an analgesic undercurrent that distinguishes it from more stimulating dissociatives — lower doses produce mild stimulation while higher doses drive deep immersive internal states. Confusion, impaired coordination, and compulsive redosing urges are common unsought effects.
Dependence liability is inferred as moderate from ketamine-class data, and no lethal dose or controlled toxicity data exist.inferred Acute risk escalates sharply in combination with depressants or stimulants, and chronic use may carry the bladder damage characteristic of the ketamine class. HXE is among the least-studied dissociatives in active circulation — one electrophysiological study and forensic case reports constitute the entire evidence base.
History[edit]
Discovery
O-Desmethylmethoxetamine — later marketed as HXE — was first described in 2013 not as a drug but as the primary metabolite of methoxetamine. Meyer et al. identified it as the O-demethylation product of MXE using rat and human urine samples.[2] Horsley et al. confirmed it as MXE's most abundant urinary metabolite in Wistar rats,[3] and Hajkova et al. independently synthesized it as a forensic reference standard.[5]
The methoxetamine wave
MXE emerged around 2010 as a purported "bladder-friendly" alternative to ketamine, quickly becoming one of the most widely used dissociative new psychoactive substances of the early 2010s.[6][3] International scheduling followed: the United Kingdom imposed Class B controls in 2013,[7] France and Germany classified it the same year, and the United States placed MXE in Schedule I in 2022.[8] This progressive prohibition created the market vacuum that HXE would fill.
Market entry
HXE appeared on designer drug markets as a standalone substance in late 2019,[9] part of a broader pattern in which metabolites and structural derivatives of scheduled dissociatives are repurposed as primary drugs.[10] The Center for Forensic Science Research and Education documented HXE's first confirmed toxicology case in November 2021,[4] and the French addictovigilance network has since placed it under active surveillance as an emerging ketamine-structural analog NPS.[11]
The name "hydroxetamine" is a market coinage blending "hydroxy" (from the 3-hydroxyphenyl group that distinguishes it from MXE's 3-methoxyphenyl) with the "-etamine" suffix common to ketamine-derived naming. The abbreviation HXE parallels MXE for methoxetamine. In user communities, HXE's reputation centers on being MXE's metabolite that turned out to be active on its own — a substance whose existence was documented by forensic chemists before anyone thought to take it deliberately.
Chemistry[edit]
Structural class
HXE belongs to the arylcyclohexylamine family — compounds defined by a cyclohexane ring bonded to a phenyl group and an amine nitrogen. More precisely, it is a β-keto arylcyclohexylamine: the cyclohexane ring carries a ketone, placing HXE in the same structural series as ketamine and methoxetamine rather than the non-keto series exemplified by phencyclidine.
Structurally, HXE is the O-demethylation product of methoxetamine: where MXE carries a 3-methoxy group on the phenyl ring (–OCH₃), HXE carries a 3-hydroxy group (–OH) at the same position. Compared to ketamine, HXE differs in three positions: N-ethyl rather than N-methyl, 3-hydroxy rather than 2-chloro on the phenyl ring, and no ring halogen.
Molecular identity
| Molecular formula | C₁₄H₁₉NO₂ |
| Molecular weight | 233.31 g/mol |
The core scaffold consists of a cyclohexanone ring with a quaternary carbon at C-2, bonded to an ethylamino group and a 3-hydroxyphenyl ring. The 3-hydroxy substituent is the defining structural feature distinguishing HXE from MXE and is the product of enzymatic O-demethylation.
Stereochemistry
HXE possesses a chiral center at C-2 of the cyclohexanone ring, generating (R)- and (S)-enantiomers. No data exist on the enantioselective pharmacology of HXE — the relative potencies of each enantiomer at the NMDA have not been characterized. The reported potency value was measured using the racemic mixture.[1] Commercial samples are presumed racemic.citation needed
For context, Ketamine shows marked enantioselectivity: (S)-ketamine is roughly three to four times more potent than (R)-ketamine at the NMDA receptor.[12] Whether analogous enantioselectivity exists for HXE is unknown.
Physical properties
No published data exist on the melting point, solubility, or stability of HXE in either free base or salt form. The 3-hydroxy group is expected to increase water solubility relative to MXE's 3-methoxy group and provides a site for metabolic conjugation that influences pharmacokinetics.inferred
Pharmacology[edit]
Mechanism of action
HXE is a potent NMDA receptor antagonist that blocks the ion channel at the same site as ketamine and phencyclidine. Electrophysiological measurements in mouse brain slices found HXE to be the most potent compound in a series of MXE derivatives tested — approximately twice as potent as MXE itself and exceeding deoxymethoxetamine and other analogs.[1] Molecular docking confirmed that HXE binds within the NMDA channel at the same site as MXE.[1]
Beyond NMDA receptor blockade, HXE's activity at other targets has not been directly measured. Mu-opioid receptor engagement is expected from class pharmacology — ketamine-class compounds interact with opioid receptors, which may contribute to both reinforcing properties and analgesic effects.[13][14][12] Whether HXE engages opioid receptors, and at what concentrations, remains unknown.inferred
Serotonin transporter affinity has been demonstrated for the parent compound MXE,[15] and MXE alters serotonin levels in brain regions associated with mood and reward.[16] Dopamine stimulation in reward pathways is also expected from the NMDA antagonist mechanism.[6] Neither serotonergic nor dopaminergic activity has been confirmed for HXE specifically.
Pharmacokinetics
No human pharmacokinetic study exists for HXE administered as a standalone substance. What is known comes from its role as a metabolite of MXE.
HXE is formed from MXE through O-demethylation, a primary Phase I metabolic reaction. Meyer et al. characterized this pathway alongside N-deethylation and hydroxylation, followed by Phase II conjugation.[2] Horsley et al. confirmed HXE as MXE's most abundant urinary metabolite in rats, with peak brain concentrations at 30 minutes and a high brain-to-blood ratio reflecting the class's strong penetration into the central nervous system.[3]
When HXE is taken directly, its expected metabolic fate — inferred from structural analogy — includes N-deethylation, ring hydroxylation, and conjugation of the 3-hydroxy group. Larabi et al. characterized analogous metabolic routes for a structurally related 3-hydroxy arylcyclohexylamine.[17]
Neuroscience[edit]
Where it acts
NMDA blockade disrupts the thalamocortical relay system — the brain's gating mechanism for integrating sensory information into unified conscious experience. By blocking NMDA receptors on inhibitory interneurons, HXE paradoxically excites cortical circuits while subjectively disconnecting the user from their body and environment.[12] Given HXE's potency at the NMDA receptor,[1] this disconnection threshold is likely reached at lower concentrations than for ketamine or MXE.
The reward system is also engaged: NMDA blockade disinhibits dopamine neurons in the ventral tegmental area, producing dopamine release in the nucleus accumbens.[6] This mechanism drives the reinforcing properties — and potential for compulsive use — shared across the dissociative class.
Why it matters
NMDA receptor antagonists are classified as psychoplastogens — compounds that trigger rapid structural brain changes. Blockade of tonic NMDA receptor activity sets off a cascade of glutamate release, AMPA activation, and growth factor signaling that produces new dendritic connections within hours.[12] This pathway underlies ketamine's rapid antidepressant effect and is presumed operative for HXE, though this has not been tested.
Key unknowns include whether HXE's greater NMDA potency translates to greater neuroplastic effects than ketamine or MXE, whether the (R)- and (S)-enantiomers differ in neural activity as they do for ketamine, and whether HXE engages opioid receptors at concentrations that meaningfully alter its neural profile. No neuroimaging or electrophysiological studies have been conducted with HXE in any species.
Subjective Effects[edit]
HXE produces a warm, enveloping dissociation distinguished from many arylcyclohexylamines by its analgesic quality and cognitive quieting. At lower doses, mild stimulation and gentle perceptual shifts predominate; as dose increases, the experience deepens into heavy sedation, immersive internal landscapes, and pronounced derealization. Set, setting, and prior dissociative experience substantially shape the qualitative character — the same dose can read as contemplative or disorienting depending on context.
Relative to ketamine, HXE is longer-lasting and reportedly more immersive at equivalent dissociative depth. Compared to its parent compound methoxetamine, it is described as qualitatively similar but roughly twice as potent at the NMDA,[1] requiring proportionally lower doses for equivalent intensity.
Effect Grid
A clear dissociative state establishes itself — pronounced derealization and depersonalization create a sense of observing experience from a comfortable distance. Cognitive euphoria is prominent, accompanied by introspective depth and immersion enhancement. Visual processing suppression and spatial disorientation become obvious, and internal focus deepens substantially.
Analgesic effects are now clearly apparent, with significant touch suppression and pain suppression. Motor control impairment is meaningful — walking requires deliberate effort and coordination is noticeably degraded. Sedation predominates over stimulation at this level. Dizziness and mild nausea may occur, particularly during the come-up.
Memory suppression begins to affect recall of the experience. Time alteration distorts the subjective passage of time. This tier represents the core dissociative experience for most users — deeply introspective and perceptually altered, but with retained awareness of external surroundings.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual acuity suppression · Perspective distortion · Depth perception distortion · Auditory distortion · Vestibular distortion · Ganzfeld effect · Dreaming enhancement · Music enhancement · Visual drifting · Auditory misinterpretation · Sensory deprivation · Visual haze / noise · Auditory suppression · Brightness alteration · Color alteration · Geometry · Auditory enhancement · Light sensitivity · Peripheral misidentification · Peripheral vision distortion · Sound sensitivity · Tracers · Visual breathing · Visual morphing · Holotropic state · After-images · Tinnitus · Visual processing suppression · Internal hallucinations · Environmental orbism / cubism · External hallucinations · Visual scenery slicing · Auditory hallucinations · Object transformations · Perspective hallucinations
Vestibular distortion · Ganzfeld effect · Dreaming enhancement · Music enhancement · Visual drifting · Auditory misinterpretation · Sensory deprivation · Visual haze / noise · Auditory suppression · Brightness alteration · Color alteration · Geometry · Auditory enhancement · Light sensitivity · Peripheral misidentification · Peripheral vision distortion · Sound sensitivity · Tracers · Visual breathing · Visual morphing · Holotropic state · After-images · Tinnitus · Visual processing suppression · Internal hallucinations · Environmental orbism / cubism · External hallucinations · Visual scenery slicing · Auditory hallucinations · Object transformations · Perspective hallucinations
Nystagmus (eye wobbles) · Sedation · Bodily heaviness · Body schema distortion · Muscle relaxation · Physical fatigue · Spontaneous body sensations · Nausea · Bodily pressures · Sexual arousal suppression · Appetite suppression · Breathing alteration · Dry mouth · Heart rate perception changes · Laughter fits · Nasal congestion · Pupil dilation · Tactile euphoria · Tingling / electric sensations · Stimulation · Bodily lightness · Headache · Insomnia · Salivation · Vasoconstriction · Vibrations / buzzing · Constipation · Trembling · Vomiting · Watery eyes · Yawning · Bodily dissociation · Tactile hallucination · Phantom limb sensations
Body schema distortion · Muscle relaxation · Physical fatigue · Spontaneous body sensations · Nausea · Bodily pressures · Sexual arousal suppression · Appetite suppression · Breathing alteration · Dry mouth · Heart rate perception changes · Laughter fits · Nasal congestion · Pupil dilation · Tactile euphoria · Tingling / electric sensations · Stimulation · Bodily lightness · Headache · Insomnia · Salivation · Vibrations / buzzing · Constipation · Trembling · Vomiting · Watery eyes · Yawning · Bodily dissociation · Tactile hallucination · Phantom limb sensations
Immersion enhancement · Analysis suppression · Thought deceleration · Cognitive fatigue · Confusion · Focus suppression · Information processing suppression · Memory fragmentation · Thought disorganization · Pattern recognition suppression · Conceptual thinking · Introspection enhancement · Language suppression · Motivation suppression · Suggestibility enhancement · Thought loops · Creativity enhancement · Humor enhancement · Aesthetic enhancement · Delusions of sobriety · Multiple thought streams · Novelty enhancement · Openness enhancement · Cognitive dysphoria · Amnesia · Delirium · Delusions
Cognitive fatigue · Confusion · Focus suppression · Information processing suppression · Memory fragmentation · Thought disorganization · Pattern recognition suppression · Conceptual thinking · Introspection enhancement · Language suppression · Motivation suppression · Thought loops · Creativity enhancement · Humor enhancement · Aesthetic enhancement · Delusions of sobriety · Multiple thought streams · Novelty enhancement · Openness enhancement · Cognitive dysphoria · Amnesia · Delirium · Delusions
Emotional suppression · Anxiety · Catharsis · Emotional enhancement · Empathy suppression · Dysphoria
Empathy suppression · Dysphoria
Communication suppression · Social disconnection · Craving · Sociability suppression · Flow state · Sociability enhancement · Cognitive disconnection · Boundary dissolution · Identity alteration · Ego dissolution
Flow state · Sociability enhancement · Cognitive disconnection · Boundary dissolution · Identity alteration · Ego dissolution
Time cessation
Non-dual awareness · Transpersonal feelings · Transpersonal visions · Voidness · Near-death experience · Death-rebirth sequence
Near-death experience · Death-rebirth sequence
Timeline
Initial awareness of altered state — subtle bodily lightness, mild proprioceptive shift, faint mood elevation. Effects may be ambiguous to inexperienced users.
Progressive dissociation builds steadily. Warm body high emerges, cognitive effects develop — thought deceleration, initial derealization. Nausea most likely during this phase.
Full dissociative state with maximum cognitive disconnection, derealization, and perceptual alteration. Analgesic warmth prominent. Motor control significantly impaired.
Gradual return of external awareness and bodily sensation. Residual dissociation persists — spatial disorientation and cognitive fog linger. Drowsiness often increases as resolution progresses.
Residual cognitive effects, mild mood alteration, and physical fatigue. Some users report a contemplative afterglow with subtle emotional warmth.
⚠ Do not drive or operate heavy machinery for at least 12 hours after oral HXE use.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- None
- Tolerance buildup
- moderate
- Tolerance reset
- 1.5 weeks
- Physical
- Low
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- ketamine · methoxetamine · PCP
Toxicity
Acute toxicity
No lethal dose, therapeutic index, or controlled toxicity data exist for HXE in any species. The Center for Forensic Science Research and Education has linked HXE to adverse events including deaths since November 2021,[4] though no peer-reviewed case report specific to HXE has been published.safety citation needed
The closest toxicological reference point is MXE. Fatal MXE intoxication has been documented,[18] and a fatal MXE-amphetamine combination produced deep coma, breathing failure, dangerous overheating, seizures, muscle breakdown, liver failure, and kidney failure — with MXE blood levels in the typical intoxication range, suggesting the combination drove the lethal outcome.[19]
Neurological toxicity
Acute cerebellar toxicity — presenting as loss of coordination, involuntary eye movement, and slurred speech — has been documented with MXE.[20] Seizures, slow heart rate, and dangerously low sodium levels have also been reported.[21] Whether HXE produces similar effects has not been studied, but the shared mechanism and structural similarity make these plausible risks.inferred
Urological toxicity
Chronic use of ketamine-class compounds causes progressive bladder damage — a condition known as ketamine-associated cystitis — characterized by urinary urgency, pain, reduced bladder capacity, and in severe cases, kidney damage.[22][23][24][25] MXE was marketed as having reduced bladder toxicity, but no evidence supports this claim for either MXE or HXE. The risk with chronic HXE use has not been studied but cannot be excluded.safety citation needed
Psychological risks
NMDA receptor antagonists can produce psychosis-like states at high doses — a property historically used to model schizophrenia in research.[12] At recreational doses, HXE is expected to produce paranoia, confusion, thought disorganization, and impaired reality testing, particularly at strong and heavy doses.inferred
Compulsive redosing is a recognized pattern with NMDA antagonists, driven by dopamine stimulation in reward pathways.[6] HXE's longer duration relative to ketamine may partially reduce this tendency, but community reports nonetheless note a compulsive redosing urge.citation needed
Depersonalization and derealization, while characteristic intended effects of dissociatives, can become distressing or destabilizing in vulnerable individuals. No published data exist on HXE-specific psychiatric adverse events or psychosis precipitation.
Tolerance & dependence
No tolerance or dependence data specific to HXE exist. Tolerance to NMDA antagonists develops with repeated use through receptor-level adaptation.[12]
Cross-tolerance with other dissociatives — Ketamine, methoxetamine, PCP, dextromethorphan — is expected from the shared NMDA receptor mechanism.
Ketamine dependence is documented clinically, characterized by tolerance, craving, and dose escalation without a prominent physical withdrawal.[26] MXE shows abuse potential through dopamine stimulation in reward pathways.[6] The classification of moderate abuse liability for HXE is inferred from class data and not verified against substance-specific evidence.safety citation needed
Drug interactions
Stimulants represent the most strongly evidenced risk. Fatal MXE-amphetamine combination produced dangerous overheating, muscle breakdown, and multi-organ failure at MXE blood levels within the typical range — demonstrating that combining NMDA antagonists with stimulants can be rapidly lethal.[19]
Depressants (alcohol, benzodiazepines, opioids) produce additive sedation and respiratory depression. The severity is compounded by HXE's own sedative properties at higher doses.
MAOIs pose a theoretical serotonin syndrome risk given the SERT affinity demonstrated for MXE[15] and serotonergic involvement in MXE's effects.[16]
Other NMDA antagonists (Ketamine, dextromethorphan, deschloroketamine) produce additive dissociation with unpredictable intensification.
CYP3A4 and CYP2B6 inhibitors may slow HXE clearance based on the metabolic pathways documented for MXE,[2] potentially prolonging or intensifying effects.safety citation needed
Contraindications
No substance-specific contraindication data exist for HXE. The following are inferred from ketamine and MXE class pharmacologyinferred:
Liver or kidney impairment: MXE has been associated with muscle breakdown, liver failure, and kidney failure in fatal cases.[19]
Bladder or urinary tract conditions: Chronic ketamine-class use causes progressive bladder damage.[22][23] Pre-existing bladder conditions elevate risk.
Personal or family history of psychotic disorders: NMDA antagonists can trigger or worsen psychotic episodes in predisposed individuals.[12]
Heart conditions: Ketamine-class compounds elevate heart rate and blood pressure. Individuals with uncontrolled high blood pressure or heart disease should avoid use.safety citation needed
Concurrent MAOI use: Serotonin syndrome risk from potential serotonin transporter engagement.[15]
Pregnancy: No reproductive safety data exist. NMDA receptor signaling is critical for brain development; NMDA antagonist use during pregnancy is contraindicated as a precaution.safety citation needed
Harm Reduction[edit]
Forms & Identification
HXE appears as a white to off-white crystalline powder. Because it circulates exclusively through unregulated research chemical markets, there is no quality control on what is sold as HXE. Reagent testing can help distinguish arylcyclohexylamines from other substance classes but cannot differentiate between specific compounds within the class.
Quantitative analysis through drug checking services is the only reliable method to confirm identity and purity. The potency difference between HXE and visually identical dissociative powders means that dosing assumptions from one substance cannot be transferred to another. Treat every new batch as an unknown until tested.
Guidelines
- Test every batch with reagent kits before use; consider laboratory analysis for confirmation
- Start with a low dose and wait for full onset before considering redosing — HXE's onset can be gradual, particularly by oral route
- Have a sober sitter present, especially at higher doses or with unfamiliar batches
- Use a scale accurate to the milligram — volumetric dosing for solutions is preferable to eyeballing powder
- Do not drive or operate machinery for at least 12 hours after use
- Prepare water, blankets, and a comfortable space before dosing
- If using insufflation, alternate nostrils and rinse nasal passages afterward
Set & Setting
Dissociative experiences are strongly shaped by environment and mental state. A familiar, physically safe, low-stimulation environment reduces the risk of disorientation and injury. A sober, trusted companion who can monitor for distress and physical danger is essential — dissociated individuals may not recognize when they need help.
Avoid environments with fall hazards, water, traffic, or other physical dangers. Cognitive impairment and loss of coordination are expected, not exceptional.
Aftercare & integration. The dissociative afterglow can persist for hours to days. During this period, judgment and coordination may remain subtly impaired even after the primary effects have subsided. Avoid important decisions, driving, and demanding physical activity until fully baseline.
Dissociative experiences — particularly deep or unexpected ones — can leave residual derealization or a sense of disconnection. Grounding techniques (physical contact with textured objects, cold water on the face, structured breathing, naming objects in the room) help re-establish ordinary awareness. If depersonalization or derealization persists beyond 48 hours, professional support is advisable.
Recovery & Support
Compulsive redosing and escalating use patterns are recognized risks with NMDA antagonists. If HXE use has become difficult to control, or if tolerance has led to dose escalation, professional support is appropriate. Ketamine-specific treatment resources and general substance use services are the most relevant frameworks, as no HXE-specific treatment literature exists.
Urinary symptoms — frequency, urgency, pain — developing during a period of regular use should prompt immediate medical evaluation and cessation. Ketamine-associated bladder damage is progressive but partially reversible if caught early.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Seek immediate help if the person shows seizures, loss of consciousness, extremely slow or stopped breathing, blue or grey lips, chest pain, body temperature hot to the touch, or violent and self-harming behavior. Confusion and immobility are expected at high dissociative doses — unresponsiveness to pain, abnormal breathing, or vomiting while unconscious are not.
Immediate steps:
- 1. Call emergency services immediately
- 2. Place the person in the recovery position (on their side) to prevent choking if vomiting occurs
- 3. Do not leave them alone
- 4. Do not restrain them unless they are in immediate physical danger
- 5. Monitor breathing continuously until help arrives
- 6. Do not induce vomiting
What to tell the dispatcher: Name the substance (HXE, hydroxetamine, arylcyclohexylamine dissociative), the amount taken if known, the time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect callers from prosecution when reporting a drug emergency.
Legal Status[edit]
HXE occupies a legally ambiguous position in most jurisdictions. It is not explicitly listed as a controlled substance in most countries but falls within the scope of generic arylcyclohexylamine definitions, structural analog acts, and blanket new psychoactive substance prohibitions in several major jurisdictions. The legal landscape is shaped primarily by the scheduling history of MXE and by broad structural class controls enacted in response to the dissociative NPS wave of the 2010s.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not explicitly scheduled (federal) | Not listed in the Controlled Substances Act. The Federal Analogue Act (21 U.S.C. § 813) may apply — HXE is structurally and pharmacologically similar to Schedule I MXE (scheduled July 2022[8]) and Schedule III ketamine. Application requires case-by-case legal determination.[4] |
| United Kingdom | Likely Class B (Misuse of Drugs Act 1971) | The generic arylcyclohexylamine definition captures compounds derived from 2-amino-2-phenylcyclohexanone by nitrogen or phenyl ring substitution — HXE fits this definition. Additionally subject to the Psychoactive Substances Act 2016.[7] |
| France | Likely controlled | MXE classified as stupéfiant in August 2013. HXE under active addictovigilance surveillance as an emerging ketamine-analogue NPS.[11] |
| Germany | Controlled (NpSG) | MXE controlled July 2013. The Neue-psychoaktive-Stoffe-Gesetz (2016) broadly prohibits NPS including arylcyclohexylamine derivatives. |
| Netherlands | Unclear; likely controlled | MXE placed on Opiumwet List I in July 2015. HXE status not explicitly determined. |
| Canada | Unclear; MXE Schedule I | MXE classified as Schedule I (January 2011). HXE identified in at least one Canadian toxicology case since November 2021.[4] |
| Australia | Not explicitly scheduled | No specific scheduling identified. Class-level controls via ketamine analog provisions may apply. |
Analogue act considerations
In the United States, the Federal Analogue Act treats any substance "substantially similar" in structure and pharmacological effect to a Schedule I or II substance as Schedule I when intended for human consumption. HXE meets both structural criteria (single functional group difference from MXE) and pharmacological criteria (NMDA antagonism with greater potency than MXE).[1] Prosecution under the FAA remains case-by-case, and HXE's status has not been tested in court.
In the United Kingdom, the generic arylcyclohexylamine catch-all definition captures any compound derived from the 2-amino-2-phenylcyclohexanone scaffold by substitution at the nitrogen or phenyl ring.[7] This definition unambiguously encompasses HXE, though formal legal confirmation specific to HXE has not been published.
references
- [1]
- [2] ^abcdMeyer MR, Bach M, Welter J, Bovens M, Turcant A, Maurer HH (2013) Ketamine-derived designer drug methoxetamine: metabolism including isoenzyme kinetics and toxicological detectability using GC-MS and LC-(HR-)MSn — Analytical and Bioanalytical Chemistry doi:10.1007/s00216-013-7051-6
- [3] ^abcdHorsley RR, Lhotkova E, Hajkova K, Jurasek B, Kuchar M, Palenicek T (2016) Detailed pharmacological evaluation of methoxetamine (MXE), a novel psychoactive ketamine analogue-Behavioural, pharmacokinetic and metabolic studies in the Wistar rat — Brain Research Bulletin doi:10.1016/j.brainresbull.2016.05.002
- [4]
- [5] ^Hajkova K, Jurasek B, Sykora D, Palenicek T, Miksatkova P, Kuchar M (2016) Salting-out-assisted liquid-liquid extraction as a suitable approach for determination of methoxetamine in large sets of tissue samples — Analytical and Bioanalytical Chemistry doi:10.1007/s00216-015-9221-1
- [6]